Frequent gene amplification of the receptor-activated calcium-dependent chloride channel TMEM16A (TAOS2 or ANO1) has been reported in several malignancies. However, its involvement in human tumorigenesis has not been previously studied. Here, we demonstrate a functional role for TMEM16A in tumor growth. We found TMEM16A overexpression in 80% of head and neck squamous cell carcinoma (SCCHN), which correlated with decreased overall survival in SCCHN patients. TMEM16A overexpression significantly promoted anchorageindependent growth in vitro, and loss of TMEM16A resulted in inhibition of tumor growth both in vitro and in vivo. Mechanistically, TMEM16A-induced cancer cell proliferation and tumor growth were accompanied by an increase in ERK1/2 activation and cyclin D1 induction.
Abstract:
Frequent gene amplification of the receptor-activated calcium-dependent chloride channel TMEM16A (TAOS2 or ANO1) has been reported in several malignancies. However, its involvement in human tumorigenesis has not been previously studied. Here, we demonstrate a functional role for TMEM16A in tumor growth. We found TMEM16A overexpression in 80% of head and neck squamous cell carcinoma (SCCHN), which correlated with decreased overall survival in SCCHN patients. TMEM16A overexpression significantly promoted anchorageindependent growth in vitro, and loss of TMEM16A resulted in inhibition of tumor growth both in vitro and in vivo. Mechanistically, TMEM16A-induced cancer cell proliferation and tumor growth were accompanied by an increase in ERK1/2 activation and cyclin D1 induction.
Pharmacologic inhibition of MEK/ERK and genetic inactivation of ERK1/2 (using siRNA and dominant-negative constructs) abrogated the growth effect of TMEM16A, indicating a role for MAPK activation in TMEM16A-mediated proliferation. In addition, a developmental small molecule inhibitor of TMEM16A, T16A-inh01 (A01), abrogated tumor cell proliferation in vitro.
Together, our findings provide a mechanistic analysis of the tumorigenic properties of TMEM16A, which represents a potentially novel therapeutic target. The development of small molecule inhibitors against TMEM16A may be clinically relevant for treatment of human cancers, including SCCHN. 4 We initially determined the effects of TMEM16A on tumor proliferation (in vitro and in vivo) through gain-and loss-of function experiments. Our results demonstrate that TMEM16A induces potent and specific stimulation of the ERK1/2 (as determined by phospho-ERK1/2), and contributes to the growth of cancer cell lines. These studies provide, to the best of our knowledge, the first mechanistic description of the role of TMEM16A in human malignancies and suggest that this protein may play an important role in facilitating tumor growth. 
Materials & Methods

TMEM16A Antibody and Immunoblotting:
A rabbit polyclonal serum was obtained by immunizing rabbits with an epitope (CARVLEKSLKKESRNKEKR) from exon 14 of TMEM16A. This epitope was chosen on the basis of a BLAST search that defined a unique 21 amino-acid sequence. For immunoblotting, equal amounts of protein were separated on SDS-PAGE and transferred to nitrocellulose membranes. The membranes were then probed with anti-TMEM16A serum, Phospho-ERK1/2, p44/42 ERK1/2, p-ERK5, ERK5, B-Raf, C-Raf, Phospho-AKT Ser 472, AKT (Cell Signaling), and Cyclin D1 M-20 (Santa Cruz). ß-Tubulin or actin was used as a loading control. Ras activation kit was used according to instructions (Milipore, EMD). All immunoblots were scanned at 600 dpi and post-processed using Photoshop software (Adobe Systems). Any manipulation was applied to the entire image to preserve image integrity.
Cell culture:
HEK-293T cells were obtained from ATCC. UM-SCC1 and T24 cells were obtained from the University of Michigan (a gift from Dr. Thomas Carey). EPC1 cells were a gift from Dr. H. Nakagawa. All cell lines were genotyped to establish identity within six months of experimentation. Stable overexpressing clones were made using DNA transfection or retroviral infection. Cells were selected after transduction and viable cells were pooled. Individual clones were identified by the method of limiting-dilutions. Each clone was kept for 10 passages, after which an early passage sample was thawed and used.
Plasmid/siRNA transfections, retrovirus generation, shRNA transduction:
Plasmid transfections were performed using Fugene (DNA) or Lipofectamine2000 (siRNA) according to the manufacturer's instructions. TMEM16A and TMEM16A K610A mutant were subcloned into pBabe-puro vectors. Retroviruses were generated by transfecting PhoenixAmpho cells with these plasmids. Lentiviral shRNA and retroviral particles were used to transduce cells.
Antibiotic selection was carried out. All transduction experiments were repeated at least three separate times to ensure reproducibility. GFP-tagged dominant negative ERK2 construct was previously described (21) . ERK1/2 siRNA was obtained from Cell Signaling.
Whole cell patch clamping
Whole cell patch clamping was performed as previously described (22) . All pipette solutions were previously described (22) . All experiments used a standard protocol that alternated a current-voltage (I/V) step measurement. The I/V measurement stepped the holding potential from -100 to +100 mV in 20 mV steps. All patch clamp results were normalized by the cell capacitance recorded at the start of the experiment.
MQAE fluorescence assays
MQAE chloride efflux assays were performed on cells plated onto optical Petri dishes (Matek) pre-coated with poly-L-lysine as previously described (23) . MQAE was introduced into the cells using a hypotonic shock followed by recovery for 10 min prior to the start of the experiment. The MQAE loaded cells were then mounted on the stage of an IX-81 Olympus microscope and perfused to 37°C. MQAE fluorescence intensity was captured every 15 s at the 445nm wavelength in response to excitation at 340nm, using SlideBook (3I).
The magnitude of fluorescence in each cell in the field was quantified from a circular region of interest (ROI) drawn within the cell, and the time course of fluorescence change was plotted as the average ± SEM of all ROIs in the field (typically 10 -50 cells, "n") for a single coverslip. The rate of change in fluorescence upon the switch from high chloride to low chloride was determined for each ROI. All ROIs exhibiting a positive, linear rate of change (R 2 0.75) from at least 3 separate, identical experiments (coverslips, "N") were pooled, and statistical significance was assessed for all ROI's using Student's T-test.
Cell viability assay and drug treatments:
For proliferation and viability analysis, cells were plated in 96-well optical plates at 5x10 3 cells/well. The plates were treated the following day, as indicated. One to three days after treatment, CellTiter-Glo Assay (Promega, Fitchburgh, WI) was used according to the manufacturer's directions.
Soft agar assay, anchorage-independent viability,
Soft agar assays were performed as previously described (24) . Briefly, 5x10 4 cells suspended in 0.7% agar solution were plated in a 35 mm dish on top of 1.4 % agar. Colonies were counted 3 weeks after plating. Colonies with a diameter greater than 100 μm were counted using crystal violet. Anchorage independent viability was determined by plating cells (5x10 3 ) in poly-HEMA coated plates as previously described (25) . Cell viability was assessed three days after plating.
In Vivo Growth:
All animal studies were performed under approval from the University of Pittsburgh and were performed in accordance with established guidelines. Nude mice were injected on each flank and subsequent tumor volumes were measured when a palpable tumor was noticed. Measurements of length, and width were recorded and used to determine the volume of each tumor. At the conclusion of the experiment, tumors were harvested and processed for further evaluation.
Primary tissue samples, Tissue Array:
Paired normal and tumor tissues were collected after obtaining informed consent and approval from our Institutional Review Board. Normal adjacent mucosa is defined as histologically benign appearing mucosa (as judged by an experienced pathologist) acquired from the margins of the tumor resection. Tissue arrays containing replicate cores were created from patients who underwent curative surgery for SCCHN at our institution. Staining was performed with anti-TMEM16A antisera and scored using a semi-quantitative system (H-score) and the results correlated with survival. H-score was defined as the relative intensity, scored on a 0-3 scale, multiplied by the percentage of positively stained cells. The H-scores for the population were analyzed to determine the median score. High and low expressors were categorized as having Hscores above or below the median.
Oncomine Analysis:
Data were abstracted from the Oncomine database, and used to assess the relative expression of TMEM16A in tumors versus normal adjacent mucosa. We specifically evaluated the expression the RefSeq version of TMEM16A: NM_018043.5. A fold-change of at least 3 was used as a cutoff value.
Fluorescence in situ hybridization (FISH) studies:
FISH studies were carried out on the tissue microarray using a probe for the centromere of chromosome 11 (CEP11) labeled with SpectrumGreen (Abbott Molecular, Des Plaines, IL) and a probe prepared from a BAC clone (RP11-805J14, CHRI, Oakland, CA) and labeled by nick translation with SpectrumOrange. Slide processing and scoring were described previously (26) .
Knock-out mouse experiments:
Tmem16a knock-out mice were generated as previously described (8, 9) . Tissues were obtained by dissecting the oral cavity mucosa from mice after genotyping. Tissues were snap frozen and subsequently used for immunochemistry, RT-PCR and immunoblotting as described above.
Quantitative Reverse Transcription (RT)-PCR:
The reverse transcriptions were carried out with pre-designed TaqMan primer and probe pairs as described earlier (2) . Reverse transcriptase controls were carried out for each RNA input each time. Quantitative PCR (QPCR) was performed for TMEM16A and GAPDH was used as an endogenous control. The primer and probe sequences, conditions and concentration have been described previously (4).
Statistical Analysis:
All data are reported as mean ± SEM unless stated otherwise. Cell viability and tumor xenograft measurements were analyzed with a two-tailed Student's t-test. A paired t-test was used to test for differences in TMEM16A expression between matched tumor and benign mucosa. Two-sided
Mann-Whitney rank sum test was used to test the association of overexpression of TMEM16A with 11q13 amplification and TMEM16A expression on IHC. Kaplan-Meier and log rank tests of equality of survivors were used to evaluate differences in overall survival (OS) or diseasespecific survival (DSS) by high versus low TMEM16A IHC scores, as defined by the median value. Multivariable Cox proportional hazards models were used to evaluate TMEM16A tumor protein levels as a predictor of overall survival after adjusting for age, sex and disease stage. 
Results:
TMEM16A overexpression correlates with decreased survival in SCCHN
To examine the protein expression profile, rabbit polyclonal antibody to TMEM16A, was generated and used for immunoblotting and IHC (Supplemental Figure 1a, b) . As expected, Tmem16a derived from murine tissues, migrates at a higher molecular weight (~150kDa) than human TMEM16A (~115 kDa). This is consistent with previously published data (6) . We further validated this antibody's specificity in IHC by evaluating tissues obtained from wild-type and knock-out mice. TMEM16A is endogenously expressed in benign secretory tissues such as salivary gland and breast tissue (14) . We therefore wanted to confirm that breast malignancies also overexpress TMEM16A. We used the Oncomine database to determine the expression of TMEM16A in normal and malignant tissues from a variety of tumor types. We found that while TMEM16A may be expressed at a high level in normal breast tissue, its expression is even higher in neoplastic breast tissue (Figure 1d ). This suggests that while endogenous TMEM16A expression may be high in some normal tissues, malignant cells derived from these tissues further up- Although patients whose tumors harbored TMEM16A amplification had a median survival of 50.7 months, whereas those not amplified of TMEM16A did not reach a median survival, suggesting that there may be a trend towards improved survival in patients without gene amplification. Gene amplification was not strongly correlated with protein expression.
TMEM16A promotes tumor growth and proliferation
Next, we investigated the effects of TMEM16A manipulation (through gain-of-function and loss-of-function) on the proliferation of cancer cells (Supplemental Figure 3a&b) . To evaluate the role of TMEM16A independently of 11q13 amplification, we chose to use the UM-SCC1 SCCHN cell line (that harbors 11q13 amplification) and the T24 bladder cancer cell line (that does not contain the 11q13 amplicon). Lentiviral shRNA was used to 'knock-down' TMEM16A in both cell lines. We identified two independent shRNA sequences that caused a significant reduction (~80%) in TMEM16A protein expression. TMEM16A knock-down led to a measurable change in whole cell chloride conductance (~50%), as assayed by MQAE fluorescence assays (27) (Supplemental Figure 3c- To determine the consequences of TMEM16A knock-down on in vivo tumor growth, shRNA treated UM-SCC1 cells were inoculated subcutaneously into nude mice. TMEM16A shRNA led to a significant decrease in xenograft growth (Figure 2a, b) . Further, we found that 
together, these data suggest that TMEM16A overexpression can facilitate oncogenic transformation through cooperation with potent oncogenes.
We next determined the effect of TMEM16A knockdown on in vitro growth. Treatment with TMEM16A shRNA led to a significant retardation in proliferation when compared to control shRNA (Figure 4a, b) . TMEM16A shRNA abrogated the increase in both anchoragedependent and -independent cell proliferation noted in overexpressing cells (Figure 4c, d ).
TMEM16A knock-down induced an accumulation of cells in G0/G1 and a concomitant decrease in the S/G2 phase, suggesting a block in cell cycle progression (Supplemental Figure 5A) .
Interestingly, TMEM16A overexpression impaired caspase-3/7 activation, suggesting that TMEM16A may in fact impair apoptotic cell death, along with promoting cell growth (Supplemental Figure 5B) .
TMEM16A induces phosphorylation of ERK1/2
Since we observed differential expression of pERK1/2 in tumor xenografts, we examined whether TMEM16A expression influenced ERK1/2 activation. TMEM16A overexpression was associated with an increase in phosphorylated ERK1/2 (~2 fold) and cyclin D1 (~5 fold) ( Figure   5a ). TMEM16A siRNA led to a decrease in phospho-ERK1/2 and cyclin D1 (Figure 5b ). We noted that AKT and phospho-AKT levels were not significantly influenced by TMEM16A overexpression, suggesting specificity to the ERK1/2 pathway (Figure 5b) . Similarly, there were no changes in p-ERK5 or ERK5 (Supplemental Figure 6c) It is well known that RAS oncogenic signaling can activate ERK1/2. HRAS, in particular, has been associated with SCCHN development (29, 30) . In fact, no mutations in KRAS or NRAS were observed in two recent genomic studies of SCCHN (30, 31 
presence of HRAS, KRAS and NRAS mutations in the cell lines used in this study. T24 cells harbor the activating HRASG12V mutation, however, HEK-293T, EPC1 and UM-SCC1 cells did not harbor mutant HRAS, KRAS or NRAS (data not shown). Taken together, these data suggest that the impact of TMEM16A on ERK1/2 signaling is independent of activating HRAS mutations.
Next, we explored the association between Tmem16a and cyclinD1 in oral cavity tissues obtained from wild-type and Tmem16a -/-embryos. As expected, Tmem16a levels were reduced in knock-out mouse tissues as compared to wild-type and heterozygous mice (Figure 5c ).
Interestingly, cyclin D1 was also decreased in tissues derived from knock-out mice, but not in their heterozygous or wild-type littermates. We observed intense nuclear cyclin D1 staining in the proliferative mesoderm of wild-type mice but not in the Tmem16a -/-littermates (Supplemental Figure 6a) . We further explored this finding by measuring mRNA expression of Tmem16a and Ccnd1 in these tissues. As expected, knock-out tissues had significantly lower levels of cyclin D1 (Supplemental Figure 6b) . This finding suggested that TMEM16A may be influencing cell proliferation on a fundamental level, and occurs in vivo.
We postulated that if TMEM16A affects proliferation by activating MEK/ERK, inhibition of MEK/ERK should abrogate TMEM16A-induced growth. Indeed, treatment with either UO126 or dominant-negative ERK1/2 led to a complete abrogation of TMEM16A-induced growth (Figure 5d, e) . Similar data were observed with the specific ERK inhibitor AZD6244 and with siRNA against ERK1/2 (Supplemental Figures 5c, d) . Treatment with TMEM16A shRNA reversed the activation of MEK and ERK1/2 induced by TMEM16A overexpression (Figure 5f ). This observation suggests that TMEM16A overexpression directly impacts ERK1/2 activation. Recent data suggests that ERK activation may impact the chloride conductance of TMEM16A (15) . Similarly, mutations in the putative pore forming domain can impact the whole-cell chloride conductance in forced overexpression experiments (32) . We sought to determine if the putative pore-forming region of TMEM16A was necessary for activation of ERK1/2. Forced overexpression of a mutant version of TMEM16A (TMEM16A-K610A) that has been described to display significantly abrogated chloride conductance (15), did not induce ERK1/2 or phospho-ERK1/2 (Figure 6a) . We verified that TMEM16A-K610A was trafficked to the cell membrane using biotinylation experiments (data not shown). Our data raises the intriguing possibility that TMEM16A affects ERK activation by modulating intracellular chloride levels. Unfortunately, manipulation of intracellular chloride levels can itself induce changes in the expression of ion channels. Therefore, further work is necessary to dissect the effect of intra-cellular chloride on ERK activation.
Overexpression of mutant TMEM16A-K610A did not promote anchorage-independent viability compared to vector controls (Figure 6b-d) . To confirm that the effects are indeed directly dependent on TMEM16A expression, we rescued TMEM16A shRNA treated cells with shRNA-resistant versions of TMEM16A or TMEM16A-K610A (Supplemental Figure 7a) . The reduction in viability induced by TMEM16A shRNA was rescued by expression of an shRNAresistant version of TMEM16A, but not resistant TMEM16A-K610A (Figure 6e ). This approach provides strong evidence to show that TMEM16A directly induces the proliferative phenotype.
TMEM16A activates the Ras-Raf-MEK-ERK pathway
The observation that TMEM16A induces activation of ERK1/2 led us to interrogate the 
Pharmacologic inhibition of TMEM16A induces cancer cell death
In order to validate TMEM16A as a potential target in epithelial malignancies, we wanted to determine if small molecule inhibition of TMEM16A could inhibit tumor cell proliferation.
Therefore, we treated UM-SCC1 and T24 cells with a novel TMEM16A inhibitor (T16A-inh01) (33, 34) . T16A-inh01 induced a dose dependent reduction in cell viability (Supplemental Figure   8a, b) . In order to determine whether combined inhibition of TMEM16A and MAPK had an additive effect on cell viability, we treated cells with the MEK/ERK inhibitor UO126 alone or in combination with TMEM16A shRNA. TMEM16A knock-down resulted in a modest decrease in cell proliferation, however, we observed an additive effect with MAPK inhibition (Supplemental 
Discussion:
There is accumulating evidence that chloride channels influence tumor growth and progression (35) (36) (37) , however the mechanism(s) by which this occurs remains unclear. Calciumactivated chloride channels (CaCCs) are a unique subset of chloride channels that play important roles in many fundamental physiologic processes (38, 39) . Recently, ANO1/TMEM16A was described as a bona fide CaCC (5-7). However, it remains controversial whether TMEM16A is itself a functional CaCC, or forms a subunit within the protein complex that facilitates CaCC activity (7, 40, 41) . Recent reports suggest that CaCCs can both promote and retard tumor cell proliferation (16, 17) . These contradictory reports suggest that improved understanding of the impact of CaCC regulation and activation on cell proliferation may help to define whether these molecules can serve as a future therapeutic target.
TMEM16A is frequently overexpressed in several tumors including squamous cell carcinoma of the head and neck, esophageal cancer, and gastrointestinal stromal tumors (GIST) (4, 18, 42, 43) . To date, the exact role(s) that TMEM16A plays in tumor development/progression remains unclear. Ayoub et al. have recently reported that TMEM16A overexpression facilitates cell motility and may contribute to the development of metastases (44); however, no mechanism was proposed to explain this phenotype.
This report provides the first mechanistic link between TMEM16A expression and cell proliferation in human cancer. Our data show that TMEM16A expression directly impacts cellular proliferation. TMEM16A also cooperates with oncogenic H-Ras to induce focus formation in immortalized MEF's. Taken together, these data strongly suggest that TMEM16A may function as a proto-oncogene, and that its overexpression drive tumor growth. 
It has recently been shown that TMEM16A channel activity is linked to ERK1/2 activation and that the ERK inhibitor UO126 can inhibit TMEM16A channel function (15) . Our data suggest that TMEM16A activates the Ras-Raf-MEK-ERK1/2 pathway, thereby influencing cellular proliferation. However, this activation does not occur when a hypomorphic mutant (TMEM16A-K610A) is expressed. These data raise the intriguing possibility that the chloride conductance of TMEM16A impacts ERK1/2 activation. However, the exact mechanism by which this occurs remains unclear.
The availability of small molecule inhibitors against TMEM16A provides a novel potential method to inhibit tumor cell growth. The currently available small molecule inhibitors of TMEM16A (niflumic acid and NPPB) exhibit off-target effects and have been shown to block other chloride channels. However, T16A-inh01 is a novel and potentially more specific TMEM16A inhibitor, and provides a method to inhibit channel activity (33, 34, 45) . This developmental molecule likely has off-target effects, and therefore definitive conclusions cannot be defined at this time.
The ubiquitous expression of TMEM16A suggests that the endogenous protein has important physiologic roles that may be adversely impacted by pharmacologic inhibition.
However, TMEM16A is known to undergo alternative splicing, and specific variants have been isolated from diseased tissues (such as diabetic gastroparesis) (46) (47) (48) . Recently, mutations in TMEM16A have been described in SCCHN. The existence of specific mutations in TMEM16A that have been identified from whole-exome sequencing of SCCHN, suggests that tumor-specific targeting may be possible in the future (30) . 
